Volume 12, Number 8—August 2006
Research
Carbapenem Resistance in Klebsiella pneumoniae Not Detected by Automated Susceptibility Testing
Table 1
Carbapenem susceptibility and strain typing results for isolates tested in the study*
Organism | Imipenem broth microdilution MIC† (μg/mL) and CLSI interpretation | Meropenem broth microdilution MIC (μg/mL) and CLSI interpretation | PFGE profile | Hospital identification no. |
---|---|---|---|---|
1 Klebsiella pneumoniae | 8 I | 16 R | A | 1 |
2 K. pneumoniae | 16 R | >16 R | A | 1 |
3 K. pneumoniae | 16 R | 16 R | A | 2 |
4 K. pneumoniae | 8 I | 8 I | A | 2 |
5 K. pneumoniae | 16 R | >16 R | A | 2 |
6 K. pneumoniae | 16 R | 16 R | A | 2 |
7 K. pneumoniae | 16 R | 16 R | A | 3 |
8 K. pneumoniae | 32 R | 16 R | A | 4 |
9 K. pneumoniae | 16 R | >16 R | B | 1 |
10 K. pneumoniae | 16 R | >16 R | B | 1 |
11 K. pneumoniae | 16 R | 16 R | C | 4 |
12 K. pneumoniae | 16 R | 16 R | D | 1 |
13 K. pneumoniae | 16 R | 16 R | E | 4 |
14 K. pneumoniae | 16 R | >16 R | F | 1 |
15 K. pneumoniae | 16 R | >16 R | F1 | 4 |
K. pneumoniae 1534 (control) | 16 R | >16 R | NA | NA |
Serratia marcescens 525 (control) | >16 R | >16 R | NA | NA |
*CLSI, Clinical and Laboratory Standards Institute; PFGE, pulsed-field gel electrophoresis; NA, not applicable.†Interpretations of MIC results used CLSI criteria (18); I, intermediate; R, resistant.
References
- Yigit H, Queenan AM, Anderson GJ, Sanchez-Sanchez AD, Biddle JW, Steward CD, Novel carbapenem-hydrolyzing β-lactamase, KPC-1, from a carbapenem-resistant strain of Klebsiella pneumoniae. Antimicrob Agents Chemother. 2001;45:1151–61. DOIPubMedGoogle Scholar
- Yigit H, Queenan AM, Anderson GA, Biddle JW, Steward CD, Domenech-Sanchez A, Carbapenem-resistant strain of Klebsiella oxytoca harboring carbapenem-hydrolyzing beta-lactamase KPC-2. Antimicrob Agents Chemother. 2003;47:3881–9. DOIPubMedGoogle Scholar
- Bradford PA, Bratu S, Urban C, Visalli M, Mariano N, Landman D, Emergence of carbapenem-resistant Klebsiella spp. possessing the class A carbapenem-hydrolyzing KPC-2 and inhibitor resistant TEM-30 beta-lactamases in New York City. Clin Infect Dis. 2004;39:55–60. DOIPubMedGoogle Scholar
- Smith Moland E, Hanson ND, Herrera VL, Black JA, Lockhart TJ, Hossain A, Plasmid-mediated, carbapenem-hydrolysing β-lactamase, KPC-2, in Klebsiella pneumoniae isolates. J Antimicrob Chemother. 2003;51:711–4. DOIPubMedGoogle Scholar
- Bratu S, Landman D, Alam M, Tolentino E, Quale J. Detection of KPC carbapenem-hydrolyzing enzymes in Enterobacter spp. from Brooklyn, New York. Antimicrob Agents Chemother. 2005;49:776–8. DOIPubMedGoogle Scholar
- Woodford N, Tierno PM Jr, Young K, Tysall L, Palepou MF, Ward E, Outbreak of Klebsiella pneumoniae producing a new carbapenem-hydrolyzing class A beta-lactamase, KPC-3, in a New York Medical Center. Antimicrob Agents Chemother. 2004;48:4793–9. DOIPubMedGoogle Scholar
- Yigit H, Anderson GJ, Biddle JW, Steward CD, Rasheed JK, Valera LL, Carbapenem resistance in a clinical isolate of Enterobacter aerogenes is associated with decreased expression of OmpF and OmpC analogs. Antimicrob Agents Chemother. 2002;46:3817–22. DOIPubMedGoogle Scholar
- Villar HE, Danel F, Livermore DM. Permeability to carbapenems of Proteus mirabilis mutants selected for resistance to imipenem or other beta-lactams. J Antimicrob Chemother. 1997;40:365–70. DOIPubMedGoogle Scholar
- White RL, Kays MB, Friedrich LV, Brown EW, Koonce JR. Pseudoresistance of Pseudomonas aeruginosa resulting from degradation of imipenem in an automated susceptibility testing system with pre-dried panels. J Clin Microbiol. 1991;29:398–400.PubMedGoogle Scholar
- Doern GV, Brueggemann AB, Perla R, Daly J, Halkias D, Jones RN, Multicenter laboratory evaluation of the bioMérieux VITEK antimicrobial susceptibility testing system with 11 antimicrobial agents versus members of the Family Enterobacteriaceae and Pseudomonas aeruginosa. J Clin Microbiol. 1997;35:2115–9.PubMedGoogle Scholar
- Steward CD, Wallace D, Hubert SK, Lawton R, Fridkin SK, Gaynes RP, Ability of laboratories to detect emerging antimicrobial resistance in nosocomial pathogens: a survey of Project ICARE laboratories. Diagn Microbiol Infect Dis. 2000;38:59–67. DOIPubMedGoogle Scholar
- Steward CD, Mohammed JM, Swenson JM, Stocker SA, Williams PP, Gaynes RP, Antimicrobial susceptibility testing of carbapenems: multicenter validity testing and accuracy levels of five antimicrobial test methods for detecting resistance in Enterobacteriaceae and Pseudomonas aeruginosa isolates. J Clin Microbiol. 2003;41:351–8. DOIPubMedGoogle Scholar
- Carmeli Y, Eichelberger K, Soja D, Dakos J, Venkataraman L, deGirolami P, Failure of quality control measures to prevent reporting of false resistance to imipenem, resulting in a pseudo-outbreak of imipenem-resistant Pseudomonas aeruginosa. J Clin Microbiol. 1998;36:595–7.PubMedGoogle Scholar
- Bratu S, Mooty M, Nichani S, Landman D, Gullans C, Pettinato B, Emergence of KPC-possessing Klebsiella pneumoniae in Brooklyn, New York: epidemiology and recommendations for detection. Antimicrob Agents Chemother. 2005;49:3018–20. DOIPubMedGoogle Scholar
- Bratu S, Landman D, Haag R, Recco R, Eramo A, Alam M, Rapid spread of carbapenem-resistant Klebsiella pneumoniae in New York City: a new threat to our antibiotic armamentarium. Arch Intern Med. 2005;165:1430–5. DOIPubMedGoogle Scholar
- National Committee for Clinical Laboratory Standards (NCCLS). Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard–sixth edition. NCCLS document M7–A6. Wayne (PA): The Committee; 2003.
- National Committee for Clinical Laboratory Standards (NCCLS). Performance standards for antimicrobial disk susceptibility tests; approved standard–eighth edition. NCCLS document M2–A8. Wayne (PA): The Committee; 2003.
- Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; Fifteenth informational supplement M100–S15. Wayne (PA): The Institute; 2005.
Page created: December 09, 2011
Page updated: December 09, 2011
Page reviewed: December 09, 2011
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.